# A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

> **NCT05201118** · PHASE1 · UNKNOWN · sponsor: **Chunrui Li** · enrollment: 20 (estimated)

## Conditions studied

- Extramedullary Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** CT103A

## Key facts

- **NCT ID:** NCT05201118
- **Lead sponsor:** Chunrui Li
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05201118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05201118, "A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05201118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*